Korea Investment CORP Buys 4,677 Shares of Thermo Fisher Scientific Inc. $TMO

Korea Investment CORP boosted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 261,399 shares of the medical research company’s stock after purchasing an additional 4,677 shares during the period. Korea Investment CORP’s holdings in Thermo Fisher Scientific were worth $151,468,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. High Note Wealth LLC lifted its position in Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 29 shares during the period. Swiss RE Ltd. bought a new position in Thermo Fisher Scientific during the fourth quarter valued at approximately $28,000. JPL Wealth Management LLC purchased a new stake in Thermo Fisher Scientific during the third quarter valued at approximately $28,000. Beacon Financial Strategies CORP purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $29,000. Finally, Olistico Wealth LLC purchased a new stake in Thermo Fisher Scientific during the fourth quarter valued at approximately $29,000. Institutional investors own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the transaction, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages have commented on TMO. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. HSBC cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their target price for the company from $670.00 to $540.00 in a report on Wednesday, June 3rd. Robert W. Baird reduced their target price on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a report on Friday, April 24th. DZ Bank began coverage on shares of Thermo Fisher Scientific in a report on Friday, March 27th. They set a “buy” rating and a $610.00 target price for the company. Finally, Piper Sandler began coverage on shares of Thermo Fisher Scientific in a report on Thursday. They set a “neutral” rating and a $510.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $608.95.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO opened at $468.80 on Friday. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $643.99. The stock has a market capitalization of $174.22 billion, a P/E ratio of 25.77, a PEG ratio of 2.11 and a beta of 0.88. The firm has a fifty day simple moving average of $479.14 and a two-hundred day simple moving average of $527.68. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 EPS for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The business had revenue of $11.01 billion during the quarter, compared to analysts’ expectations of $10.86 billion. During the same period last year, the company posted $5.15 EPS. The business’s revenue was up 6.2% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, analysts expect that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend is Monday, June 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.